Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omalizumab + budesonide + formoterol
- Development stage
- Phase 3
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous, Inhalation
01
Overview
Omalizumab + budesonide + formoterol is a combination therapy used primarily for the treatment of moderate to severe allergic asthma. Omalizumab is a monoclonal antibody that binds to immunoglobulin E (IgE), preventing it from attaching to mast cells and basophils, thereby reducing allergic inflammation. Budesonide is an inhaled corticosteroid that reduces airway inflammation, while formoterol is a long-acting beta-2 adrenergic agonist (LABA) that relaxes bronchial smooth muscle and improves airflow. This combination has demonstrated improved clinical efficacy in controlling asthma symptoms, enhancing pulmonary function, and improving immune function compared to standard therapies alone[1][3][4][6]. Omalizumab is typically administered via subcutaneous injection; budesonide/formoterol as an inhalation therapy.
- Brand names
- Symbicort
02
Targets
ADRB2 (β2)GR (Glucocorticoid receptor)IgE (Immunoglobulin E)
Beyond the preview
Go deeper on omalizumab + budesonide + formoterol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omalizumab + budesonide + formoterol.